Cruz, P.; Lam, J.M.; Abdalla, J.; Bell, S.; Bytyci, J.; Brosh-Nissimov, T.; Gill, J.; Haidar, G.; Hoerger, M.; Maor, Y.;
et al. Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens. Vaccines 2025, 13, 19.
https://doi.org/10.3390/vaccines13010019
AMA Style
Cruz P, Lam JM, Abdalla J, Bell S, Bytyci J, Brosh-Nissimov T, Gill J, Haidar G, Hoerger M, Maor Y,
et al. Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens. Vaccines. 2025; 13(1):19.
https://doi.org/10.3390/vaccines13010019
Chicago/Turabian Style
Cruz, Pedro, Jie Min Lam, Jehad Abdalla, Samira Bell, Jola Bytyci, Tal Brosh-Nissimov, John Gill, Ghady Haidar, Michael Hoerger, Yasmin Maor,
and et al. 2025. "Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens" Vaccines 13, no. 1: 19.
https://doi.org/10.3390/vaccines13010019
APA Style
Cruz, P., Lam, J. M., Abdalla, J., Bell, S., Bytyci, J., Brosh-Nissimov, T., Gill, J., Haidar, G., Hoerger, M., Maor, Y., Pagliuca, A., Raffi, F., Samuels, F., Segev, D., Ying, Y., & Lee, L. Y. W., on behalf of the Global Immunocompromised Health Coalition.
(2025). Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens. Vaccines, 13(1), 19.
https://doi.org/10.3390/vaccines13010019
